CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population

Objectives To study the correlation between CYP3A5 genotype and quinine 3-hydroxylation in black Tanzanian and Swedish Caucasians as well as to investigate the interethnic differences in CYP3A activity between the two populations. Methods Tanzanian (n=144) and Swedish (n=136) healthy study participants were given a single oral 250 mg dose of quinine hydrochloride and a 16-h post-dose blood sample was collected. The metabolic ratio of quinine/3-hydroxyquinine was determined in plasma by high-performance liquid chromatography. All the participants were genotyped for the known mutations of CYP3A5, which are relevant for the respective population. Correlation between quinine metabolic ratio and CYP3A5 genotype as well as the interethnic difference in CYP3A activity between the two populations was studied. Results Tanzanians had significantly higher (P<0.0001) mean quinine metabolic ratio (9.5±3.5) than Swedes (7.6±3.1). As expected, the frequency of high CYP3A5 expression alleles was higher in Tanzanians (51%) than in Swedes (7%). The mean±SD quinine metabolic ratio (10.7±3.9) in Tanzanians homozygous for low CYP3A5 expression gene was significantly higher than the corresponding mean metabolic ratio in participants heterozygous (9.5±3.3; P=0.02) or homozygous (8.1±3.1; P=0.002) for high expression CYP3A5 alleles, respectively. A tendency to higher quinine metabolic ratio in Swedes with low expression alleles compared with those with one or two high expression alleles was observed. Tanzanians homozygous for low CYP3A5 expression gene (i.e. only CYP3A4 is expressed) had significantly (P<0.0001) higher quinine metabolic ratio (10.7±3.9) than corresponding Swedes (7.7±3.1). Conclusions Clear interethnic differences were observed in the activity of CYP3A between Tanzanians and Swedes. A significant association is noted between CYP3A5 genotype and quinine 3-hydroxylation in Tanzanians, indicating a significant contribution of CYP3A5 to total 3A activity. The CYP3A4 catalyzed hydroxylation of quinine (two low CYP3A5 expression alleles) was lower in Tanzanians than in Swedes.

[1]  T. Rebbeck,et al.  CYP3A4, CYP3A5, and CYP3A43 Genotypes and Haplotypes in the Etiology and Severity of Prostate Cancer , 2004, Cancer Research.

[2]  F. Guengerich,et al.  Cytochrome P-450 3A4: regulation and role in drug metabolism. , 1999, Annual review of pharmacology and toxicology.

[3]  L. Bertilsson,et al.  The roles of cytochrome P450 3A4 and lA2 in the 3‐hydroxylation of quinine in vivo , 1999, Clinical pharmacology and therapeutics.

[4]  J. Kolars,et al.  Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[5]  H. Dienemann,et al.  The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. , 2003, Pharmacogenetics.

[6]  David B. Witonsky,et al.  CYP3A variation and the evolution of salt-sensitivity variants. , 2004, American journal of human genetics.

[7]  P. Vouros,et al.  Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[8]  B. Ring,et al.  Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. , 1998, Pharmacogenetics.

[9]  M. Haberl,et al.  The genetic determinants of the CYP3A5 polymorphism. , 2001, Pharmacogenetics.

[10]  D. Greenblatt,et al.  The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates , 2005, Clinical Pharmacokinetics.

[11]  L. Bertilsson,et al.  Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man , 2003, European Journal of Clinical Pharmacology.

[12]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[13]  R. Kim,et al.  Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A , 1999, Clinical pharmacology and therapeutics.

[14]  B. Brodie,et al.  Metabolic products of the cinchona alkaloids in human urine. , 1951, The Journal of biological chemistry.

[15]  P. Hopkins,et al.  Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4 , 1999, Clinical pharmacology and therapeutics.

[16]  Ernest Hodgson,et al.  Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. , 2003, Pharmacogenetics.

[17]  C. Clarke,et al.  CYP3A5 Genotype and Midazolam Clearance in Australian Patients Receiving Chemotherapy , 2004, Clinical pharmacology and therapeutics.

[18]  M. Romkes,et al.  In vivo modulation of CYP enzymes by quinidine and rifampin , 2000, Clinical pharmacology and therapeutics.

[19]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[20]  E. Schuetz,et al.  Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. , 2002, Molecular pharmacology.

[21]  U. Yasar,et al.  Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[22]  Jin‐ding Huang,et al.  Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[23]  D. Shen,et al.  Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[24]  E. Schuetz,et al.  Genetic contribution to variable human CYP3A-mediated metabolism. , 2002, Advanced drug delivery reviews.

[25]  L. Gustafsson,et al.  Simultaneous determination of quinine and four metabolites in plasma and urine by high-performance liquid chromatography. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[26]  K. Chiba,et al.  Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450. , 1996, The Journal of pharmacology and experimental therapeutics.

[27]  L. Bertilsson,et al.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. , 2002, British journal of clinical pharmacology.

[28]  N. White,et al.  Antimalarial pharmacokinetics and treatment regimens. , 1992, British journal of clinical pharmacology.

[29]  H. Whittle,et al.  Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West Africa. , 2004, Pharmacogenetics.

[30]  C. Alm,et al.  Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. , 1999, Pharmacogenetics.

[31]  Kamolrat Silamut,et al.  Randomized comparison of artesunate and quinine in the treatment of severe falciparum malaria. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[33]  J. Miners,et al.  Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine. , 2003, British journal of clinical pharmacology.

[34]  J. Reddy,et al.  Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  K. Shimokata,et al.  Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. , 1999, Journal of the National Cancer Institute.

[36]  W. Trager,et al.  Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. , 1994, The Journal of pharmacology and experimental therapeutics.

[37]  M. Ingelman-Sundberg,et al.  Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[38]  J. Witte,et al.  CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′‐promoter region polymorphism , 2000, Clinical pharmacology and therapeutics.

[39]  R. Tyndale,et al.  Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. , 1998, Pharmacogenetics.

[40]  Ingrid V. Botnen,et al.  Characterization of common CYP1B1 variants with different capacity for benzo[a]pyrene-7,8-dihydrodiol epoxide formation from benzo[a]pyrene. , 2005, Cancer research.

[41]  Y. Sugiyama,et al.  In Vitro/in Vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans , 2001, Biopharmaceutics & drug disposition.

[42]  P. Coville,et al.  Metabolism of Quinine in Man: Identification of a Major Metabolite, and Effects of Smoking and Rifampicin Pretreatment , 1995, The Journal of pharmacy and pharmacology.

[43]  K. Dalhoff,et al.  Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients , 2001, Clinical pharmacology and therapeutics.

[44]  R. Kim,et al.  Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. , 2003, Pharmacogenetics.

[45]  M. Ingelman-Sundberg,et al.  Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. , 1999, Biochemical and biophysical research communications.

[46]  J. Azuma,et al.  CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers , 2004, The Pharmacogenomics Journal.

[47]  M. Ingelman-Sundberg,et al.  A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. , 2003, British journal of clinical pharmacology.

[48]  L. Bertilsson,et al.  Metabolism and elimination of quinine in healthy volunteers , 2003, European Journal of Clinical Pharmacology.

[49]  K. Brøsen,et al.  Quinidine as a probe for CYP3A4 activity: Intrasubject variability and lack of correlation with probe‐based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6 , 2000, Clinical pharmacology and therapeutics.

[50]  L. Bertilsson,et al.  The karolinska cocktail for phenotyping of five human cytochrome P450 enzymes , 2003, Clinical pharmacology and therapeutics.

[51]  C. Alm,et al.  Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype , 1998, Clinical pharmacology and therapeutics.

[52]  P. Coville,et al.  Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. , 1995, British journal of clinical pharmacology.

[53]  E. Skjelbo,et al.  Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. , 1999, British journal of clinical pharmacology.

[54]  T. Strandberg,et al.  CYP3A5 Genotype is Associated with Diagnosis of Hypertension in Elderly Patients , 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.